Pavan Bachireddy, M.D.
Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Scientific Director, ECLIPSE (Evolution of Cancer, Leukemia and Immunity Post Stem cEll transplant), The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Immunology and Quantitative Sciences, GSBS, University of Texas Graduate School of Biomedical Sciences, Houston, Texas
Assistant Professor (Joint appointment), Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
The Bachireddy
laboratory leverages high dimensional data in blood cancers to deconvolute
co-evolving cancer-immune interactions in the microenvironment that dictate
patient immunotherapeutic outcomes. Integrated with functional genomic
perturbations, such insights will transform our understanding of disease
pathogenesis and nominate targets for developing next generation
immunotherapies
Education & Training
Degree-Granting Education
| 2009 | Stanford University School of Medicine, Stanford, California, US, Medicine, MD |
| 2003 | Harvard University, Cambridge, Massachusetts, US, Biochemical Sciences, AB, Magna Cum Laude |
Postgraduate Training
| 2012-2015 | Clinical Fellowship, Medical Oncology, Dana-Farber Cancer Institute, Harvard Cancer Center, Boston, Massachusetts |
| 2009-2012 | Clinical Residency, Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts |
| 2009-2015 | Clinical Fellowship, Medicine, Harvard Medical School,, Boston, Massachusetts |
Licenses & Certifications
| 2015 | Medical Oncology |
Experience & Service
Faculty Academic Appointments
Instructor, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 2015 - 2021
Administrative Appointments/Responsibilities
Scientific Director, ECLIPSE (Evolution of Cancer, Leukemia and Immunity Post Stem cEll transplant), The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Other Professional Positions
Attending Physician in Medicine, Brigham & Women’s Hospital, Boston, MA, 2015 - 2021
Intramural Institutional Committee Activities
Search Committee, Member of Search Committee for Chair of Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 2026 - Present
Committee member, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2026 - Present
Advisory Committee, Member of Advisory Committee for Chair of Department of Hematopoietic Biology & Malignancy, The University of Texas MD Anderson Cancer Center, 2021 - 2021
Extramural Institutional Committee Activities
Reviewer, Grant reviewer for MDACC CPRIT HIHR program, The University of Texas MD Anderson Cancer Center, 2024 - Present
Reviewer, Reviewer for the FY23 Division of Cancer Medicine Employee Recognition & Awards Program, The University of Texas MD Anderson Cancer Center, 2023 - 2023
Reviewer, Reviewer for the FY22 Division of Cancer Medicine Employee Recognition & Awards Program, The University of Texas MD Anderson Cancer Center, 2022 - 2022
Co-Leader, Cancer Program Working Group on Immuno-Oncology, Broad Institute of MIT and Harvard, The University of Texas MD Anderson Cancer Center, 2018 - 2019
Associate Member, Associate Member, American Association of Cancer Research, 2013 - Present
Associate Member, Associate Member, American Society of Clinical Oncology, 2013 - Present
Member, Member, American Society of Hematology, 2012 - Present
Member, Member, Massachusetts Medical Society, 2009 - 2012
Active Member, Active Member, American Association for Cancer Research, 2006 - 2009
Honors & Awards
| 2023 | Damon Runyon Clinical Investigator, Damon Runyon Cancer Research Foundation |
| 2023 | Andrew Sabin Family Fellow, Andrew Sabin Family Foundation |
| 2022 | ASCI's 2022 Young Physician-Scientist Awards (YPSAs), The American Society for Clinical Investigation |
| 2021 | CPRIT Scholar in Cancer Research, Cancer Prevention and Research Institute of Texas |
| 2021 | UT Rising STARs |
| 2019 | Amy Strelzer Manasevits Scholar Award, Be The Match Foundation |
| 2019 | Clinical Fellow Scholar Award, American Society of Hematology |
| 2019 | Award Finalist, Burroughs Wellcome Fund Career Award for Medical Scientists |
| 2019 | Junior Faculty Clinician Scientist Distinguished Young Investigator Research Award - Annual Immuno-Oncology Young Investigators’ Forum, Society for Immunotherapy of Cancer |
| 2015 - 2019 | Damon Runyon Cancer Research Foundation Physician-Scientist Award, Damon Runyon Cancer Research Foundation |
| 2015 | Young Investigator Award, Conquer Cancer Foundation and American Society of Clincial Oncology |
| 2015 | Young Investigator Award, American Society for Blood and Marrow Transplantation (awarded then returned because of receipt of DRCRF award below) |
| 2014 | Young Investigator Travel Award, Society of Hematologic Oncology |
| 2012 | Abstract Achievement Award, American Society of Hematology |
| 2006 | Scholar-in-Training Award, American Association for Cancer Research |
| 2003 | Harvard College Scholarship, Harvard College |
| 1998 | Eagle Scout Award, Boy Scouts of America |
Selected Presentations & Talks
Local Presentations
- 2026. T cell dysfunction at the leukemic apex. Invited. Zeev Estrov Leukemia Lecture. Houston, Texas, US.
- 2026. State, fate and selection in silent remission: the hidden phase of relapse. Invited. Systems Biology Seminar Series. Houston, Texas, US.
- 2022. Deconvolving (un)successful anti-cancer immunity. Invited. Leading Edge of Cancer Symposium. Houston, Texas, US.
- 2022. Using single-cell multi-omic strategies to deconvolute leukemia and immune cell evolutionary trajectories. Invited. UT MD Anderson Data Science & Modeling Forum. Houston, TX, US.
- 2021. Unbiased discovery of the biological determinants of the graft versus leukemia effect. Invited. Department of Pathology and Laboratory Medicine Grand Rounds. Houston, Texas, US.
- 2021. Unbiased discovery of the molecular and cellular pathways animating GvL. Invited. Unbiased discovery of the molecular and cellular pathways animating GvL. Houston, TX, US.
Regional Presentations
- 2026. The varying roads to relapse: how leukemic stem cells adapt and evade immune control. Invited. Center for Cell and Gene Therapy. Houston, Texas, US.
- 2022. Deconstructing the leukemic microenvironment with single cell multi-omic tools. Invited. Texas Single Cell Seminar, US.
- 2021. Leaving the nest. Invited. Trainee Retreat. Cambridge, MA, US.
- 2019. “Clonal and single cell dynamics of resistance to GvL in CLL”. Conference. “Clonal and single cell dynamics of resistance to GvL in CLL”, US.
- 2018. “Cancer-germline antigens discriminate clinical outcome to CTLA-4 blockade”. Conference. “Cancer-germline antigens discriminate clinical outcome to CTLA-4 blockade”. Boston, MA, US.
- 2016. “Understanding DLI”. Conference. “Understanding DLI”. Boston, MA, US.
- 2016. “Haematologic malignancies: challenges and opportunities for immunotherapeutic innovation”. Conference. “Haematologic malignancies: challenges and opportunities for immunotherapeutic innovation”, US.
National Presentations
- 2026. Molecular tools to decode MRD progression. Invited. 5th Joint ASTCT/EBMT Basic and Translational Scientific Meeting. Philadelphia, US.
- 2025. Identifying, Understanding and Eradicating MRD in Patients with AML. Invited. Break Through Cancer Annual Summit.
- 2025. ASXL1 marks the spot: a story of suppression. Invited. AACR CIMM Town Hall, US.
- 2021. Cancer-germline antigens discriminate clinical outcome to CTLA-4 blockade. Conference. Cancer-testis antigens seminar, US.
International Presentations
- 2026. Clonal tracking reveals molecular insights from CART to MRD evolution. Invited. University Hospital of Augsburg, Department of Stem Cell Transplantation. Augsburg, DE.
- 2024. ASXL1 marks the spot: a story of suppression. Invited. Oncogene Driven Immune Escape. Freiburg, DE.
- 2022. Defining mechanisms of immunotherapeutic sensitivity in leukemia: high-resolution molecular tools and probabilistic-based approaches. Invited. OncoEscape Collaborative Research Center 1479. Freiburg, DE.
- 2021. Cancer-germline antigens discriminate clinical outocme to CTLA-4 blockade. Invited. Cancer-testis antigens. Rockville, US.
Formal Peers
- 2021. Unbiased discovery of the biological determinants of the graft versus leukemia effect. Invited. Houston, TX, US.
- 2021. Leaving the nest. Invited. Boston, MA, US.
- 2021. Leaving the nest. Invited. Boston, MA, US.
- 2018. “Understanding clinical outcomes to CTLA-4 blockade”. Invited. Freiburg, DE.
Grant & Contract Support
| Date: | 2023 - 2026 |
| Title: | Defining the molecular drivers of immune escape in MDS |
| Funding Source: | Edward P. Evans Foundation |
| Role: | PI |
| Date: | 2023 - 2025 |
| Title: | Determining the immunosuppressive impact of MRD progression in AML |
| Funding Source: | Sabin Family Foundation Fellowship Award |
| Role: | PI |
| Date: | 2023 - 2028 |
| Title: | Deconstructing the immune evasive circuits that define MRD progression of myelodysplastic syndrome |
| Funding Source: | Damon Runyon Cancer Research Foundation |
| Role: | PI |
| Date: | 2023 - 2027 |
| Title: | Targeting Clonal Hematopoiesis (CH) to Prevent Acute Myeloid Leukemia (AML) |
| Funding Source: | Break Through Cancer - BTC |
| Role: | Co-PI |
| Date: | 2023 - 2027 |
| Title: | Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) |
| Funding Source: | Break Through Cancer - BTC |
| Role: | Co-PI |
| Date: | 2021 - 2022 |
| Title: | CCSG New Faculty Award |
| Funding Source: | MDACC CCSG New Faculty Award |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Deconvolving mechanisms of GvL sensitivity and resistance in myeloid malignancies |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR210008 |
| Date: | 2020 - 2025 |
| Title: | Elucidating human leukemia and T cell interactions within the tumor microenvironment |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1K08CA248458-01 |
| Date: | 2019 - 2024 |
| Title: | Coevolution of leukemia and immune cells during GvL response and resistance |
| Funding Source: | The National Marrow Donor Program (Be The Match) |
| Role: | PI |
| Date: | 2019 - 2022 |
| Title: | Co-evolution of lymphoma and immune cells following neoantigen vaccination in patients with follicular lymphoma or chronic lymphocytic leukemia |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | PI |
| Date: | 2015 - 2019 |
| Title: | Coevolution of tumor and T cell heterogeneity following immunotherapy |
| Funding Source: | Damon Runyon Cancer Research Foundation |
| Role: | PI |
| Date: | 1978 - 2016 |
| Title: | Graduate Training in Cancer Research |
| Funding Source: | NIH/NCI |
| Role: | Training Assistant |
| ID: | T32CA009172-39 |
Selected Publications
Peer-Reviewed Articles
- Chen YH, Bi T, Xu M, Lee J, Lu WS, Zhuang M, Velarde AM, McCurry D, Yang H, Al-Atrash G, Rondon G, Shpall EJ, Jelloul FZ, Cervoni-Curet FN, Ghanem S, Kerros C, Koppikar P, Molldrem J, Garcia-Manero Guillermo, Casellas R, Patel A, Bachireddy P. Interferon-g signaling shapes myelodysplastic syndrome relapse during clinically silent remission. Science. e-Pub 2026.
- Jallouk AP, Ge Z, Kaimal V, Zhang K, Lauron EJ, Robbins PB, Roberts ZJ, Danson E, Richard M, Devashish P, Neelapu S, Bachireddy P. Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion. Cancer Discovery. e-Pub 2026.
- Nicholas J Short, Pavan Bachireddy, Alex Bataller, Courtney D DiNardo, Guillermo Montalban-Bravo, Sa A Wang, Wei Wang, Abhishek Maiti, Daniel Nguyen, Maria C Hachem, Timothy M Bi, Ghayas C Issa, Kelly S Chien, Maro Ohanian, Tapan M Kadia, Sanam Loghavi, Omer Karrar, Hyunsoo Hwang, Xuelin Huang, Guillermo Garcia-Manero, Farhad Ravandi. Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study, 2026. e-Pub 2026. PMID: 42365365.
- Chen YH, Bi T, Xu M, Lee J, Lu WS, Zhuang M, Velarde AM, McCurry D, Yang H, Al-Atrash G, Rondon G, Shpall E, Jelloul FZ, Cervoni-Curet FN, Ghanem S, Kerros C, Koppikar P, Molldrem J, Garcia-Manero G, Patel A, Bachireddy P. Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes. bioRxiv, 2025. e-Pub 2025. PMID: 41279348.
- Penter L, Maurer K, Cieri N, Lu W, Lyu H, Selig M, Joosten M, Ihlow J, Li S, Livak KJ, Bullinger L, Ritz J, Bachireddy P, Davids MS, Garcia JS, Soiffer RJ, Wu CJ. Mechanisms of immune escape and extramedullary tropism in leukemia cutis. Blood 147(1):35-47, 2025. e-Pub 2025. PMID: 41026928.
- McCurry D, Ge Z, Lee J, Pasumarthi R, Leng X, Koehnke T, Pasvolsky O, Raparla P, Nguyen V, Maurer K, Li S, Livak KJ, Danson E, Thakkar B, Azizi E, Soiffer RJ, Shukla SA, Majeti R, Ritz J, Wu CJ, Molldrem JJ, Bachireddy P. ASXL1 truncating mutations drive leukemic resistance to T cell attack. bioRxiv, 2025. e-Pub 2025. PMID: 40661385.
- Maurer K, Park CY, Mani S, Borji M, Raths F, Gouin KH 3rd, Penter L, Jin Y, Zhang JY, Shin C, Brenner JR, Southard J, Krishna S, Lu W, Lyu H, Abbondanza D, Mangum C, Olsen LR, Lawson MJ, Fabani M, Neuberg DS, Bachireddy P, Glezer EN, Farhi SL, Li S, Livak KJ, Ritz J, Soiffer RJ, Wu CJ, Azizi E. Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy. Sci Immunol 10(103):eadr0782, 2025. e-Pub 2025. PMID: 39854478.
- Maurer K, Park CY, Mani S, Borji M, Penter L, Jin Y, Zhang JY, Shin C, Brenner JR, Southard J, Krishna S, Lu W, Lyu H, Abbondanza D, Mangum C, Olsen LR, Neuberg DS, Bachireddy P, Farhi SL, Li S, Livak KJ, Ritz J, Soiffer RJ, Wu CJ, Azizi E. Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy. bioRxiv, 2024. e-Pub 2024. PMID: 38405900.
- Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, Broséus J, Hergalant S, Guièze R, Li S, Zhang W, Johnson C, Long JM, Yin S, Werner L, Anandappa A, Purroy N, Gohil S, Oliveira G, Bachireddy P, Shukla SA, Huang T, Khoury JD, Thakral B, Dickinson M, Tam C, Livak KJ, Getz G, Neuberg D, Feugier P, Kharchenko P, Wierda W, Olsen LR, Jain N, Wu CJ. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell 41(10):1803-1816.e8, 2023. e-Pub 2023. PMID: 37738974.
- Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen NM, Pfaff KL, Cieri N, Oliveira G, Kim-Schulze S, Ranasinghe S, Leonard R, Robertson T, Morgan EA, Chen HX, Song MH, Thurin M, Li S, Rodig SJ, Cibulskis C, Gabriel S, Bachireddy P, Ritz J, Streicher H, Neuberg DS, Hodi FS, Davids MS, Gnjatic S, Livak KJ, Altreuter J, Michor F, Soiffer RJ, Garcia JS, Wu CJ. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood 141(15):1817-1830, 2023. e-Pub 2023. PMID: 36706355.
- Ouspenskaia T, Law T, Clauser KR, Klaeger S, Sarkizova S, Aguet F, Li B, Christian E, Knisbacher BA, Le PM, Hartigan CR, Keshishian H, Apffel A, Oliveira G, Zhang W, Chen S, Chow YT, Ji Z, Jungreis I, Shukla SA, Justesen S, Bachireddy P, Kellis M, Getz G, Hacohen N, Keskin DB, Carr SA, Wu CJ, Regev A. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol 40(2):209-217, 2022. e-Pub 2022. PMID: 34663921.
- Penter L, Gohil SH, Huang T, Thrash EM, Schmidt D, Li S, Severgnini M, Neuberg D, Hodi FS, Livak KJ, Zeiser R, Bachireddy P, Wu CJ. Coevolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Adv 5(22):4701-4709, 2021. e-Pub 2021. PMID: 34432868.
- Bachireddy P, Azizi E, Burdziak C, Nguyen VN, Ennis CS, Maurer K, Park CY, Choo ZN, Li S, Gohil SH, Ruthen NG, Ge Z, Keskin DB, Cieri N, Livak KJ, Kim HT, Neuberg DS, Soiffer RJ, Ritz J, Alyea EP, Pe'er D, Wu CJ. Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep 37(6):109992, 2021. e-Pub 2021. PMID: 34758319.
- Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, Chen H, Thurin M, Rodig SJ, Severgnini M, Cibulskis C, Gabriel S, Livak KJ, Cutler C, Antin JH, Nikiforow S, Koreth J, Ho VT, Armand P, Ritz J, Streicher H, Neuberg D, Hodi FS, Gnjatic S, Soiffer RJ, Liu XS, Davids MS, Bachireddy P, Wu CJ. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood 137(23):3212-3217, 2021. e-Pub 2021. PMID: 33720354.
- Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, Holden R, Sarkizova S, Gohil SH, Redd RA, Sun J, Elagina L, Giobbie-Hurder A, Zhang W, Peter L, Ciantra Z, Rodig S, Olive O, Shetty K, Pyrdol J, Uduman M, Lee PC, Bachireddy P, Buchbinder EI, Yoon CH, Neuberg D, Pentelute BL, Hacohen N, Livak KJ, Shukla SA, Olsen LR, Barouch DH, Wucherpfennig KW, Fritsch EF, Keskin DB, Wu CJ, Ott PA. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med 27(3):515-525, 2021. e-Pub 2021. PMID: 33479501.
- Bachireddy P, Ennis C, Nguyen VN, Gohil SH, Clement K, Shukla SA, Forman J, Barkas N, Freeman S, Bavli N, Elagina L, Leshchiner I, Mohammad AW, Mathewson ND, Keskin DB, Rassenti LZ, Kipps TJ, Brown JR, Getz G, Ho VT, Gnirke A, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Kharchenko PV, Wu CJ. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med 12(561), 2020. e-Pub 2020. PMID: 32938797.
- Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood 135(24):2182-2191, 2020. e-Pub 2020. PMID: 32478814.
- Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, Zhang W, Braun DA, Ligon KL, Bachireddy P, Zervantonakis IK, Rosenbluth JM, Ouspenskaia T, Law T, Justesen S, Stevens J, Lane WJ, Eisenhaure T, Lan Zhang G, Clauser KR, Hacohen N, Carr SA, Wu CJ, Keskin DB. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol 38(2):199-209, 2020. e-Pub 2020. PMID: 31844290.
- Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3(19), 2018. e-Pub 2018. PMID: 30282833.
- Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, Van Allen EM, Miao D, Huang Y, Snyder A, Merghoub T, Wolchok JD, Garraway LA, Meissner A, Weber JS, Hacohen N, Neuberg D, Potts PR, Murphy GF, Lian CG, Schadendorf D, Hodi FS, Wu CJ. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell 173(3):624-633.e8, 2018. e-Pub 2018. PMID: 29656892.
- Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ, Leukemia, Research Partnership LSBC. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med 375(2):143-53, 2016. e-Pub 2016. PMID: 27410923.
- Bachireddy P, Wu CJ. Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib. Clin Cancer Res 22(7):1547-9, 2016. e-Pub 2016. PMID: 26847060.
- Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W, Liao X, Hodi FS, O'Connell K, Haining WN, Goldstein NR, Canning CM, Soiffer RJ, Ritz J, Hacohen N, Alyea EP, Kim HT, Wu CJ. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 123(9):1412-21, 2014. e-Pub 2014. PMID: 24357730.
- Bachireddy P, Wu CJ. Understanding anti-leukemia responses to donor lymphocyte infusion. Oncoimmunology 3:e28187, 2014. e-Pub 2014. PMID: 25340010.
- Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A 108(42):17432-7, 2011. e-Pub 2011. PMID: 21969595.
- Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, Felsher DW, Thorne SH. Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res 70(23):9837-45, 2010. e-Pub 2010. PMID: 20935221.
- Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18(5):485-98, 2010. e-Pub 2010. PMID: 21035406.
- Bachireddy P, Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT. Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiat Oncol 5:105, 2010. e-Pub 2010. PMID: 21059255.
- Horoschak M, Tran PT, Bachireddy P, West RB, Mohler D, Beaulieu CF, Kapp DS, Donaldson SS. External beam radiation therapy enhances local control in pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys 75(1):183-7, 2009. e-Pub 2009. PMID: 19211195.
- Fan AC, Goldrick MM, Ho J, Liang Y, Bachireddy P, Felsher DW. A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Mol Cancer 7:74, 2008. e-Pub 2008. PMID: 18826639.
- Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 104(32):13028-33, 2007. e-Pub 2007. PMID: 17664422.
- Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A 103(44):16266-71, 2006. e-Pub 2006. PMID: 17056717.
- Bachireddy P, Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clin Cancer Res 11(12):4278-81, 2005. e-Pub 2005. PMID: 15958607.
- Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103(6):789-91, 2001. e-Pub 2001. PMID: 11171784.
Review Articles
- Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer 15(4):201-15, 2015. e-Pub 2015. PMID: 25786696.
- Bachireddy P, Rakhra K, Felsher DW. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clin Exp Immunol 167(2):188-94, 2012. e-Pub 2012. PMID: 22235994.
- Arvanitis C, Bendapudi PK, Bachireddy P, Felsher DW. Identifying critical signaling molecules for the treatment of cancer. Recent Results Cancer Res 172:5-24, 2007. e-Pub 2007. PMID: 17607933.
Other Articles
- Bachireddy P, Azizi E, Burdziak C, Nguyen VN, Ennis CS, Maurer K, Park CY, Choo ZN, Li S, Gohil SH, Ruthen NG, Ge Z, Keskin DB, Cieri N, Livak KJ, Kim HT, Neuberg DS, Soiffer RJ, Ritz J, Alyea EP, Pe'er D, Wu CJ Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep 42(8):113011, 2023. PMID: 37556329.
Editorials
- Iness AN, Bachireddy P. GPR56 in GVL: marker or mechanism?. Blood 143(13):1206-1207, 2024. PMID: 38546637.
- AIness AN, Bachireddy P. GPR56 in GVL: Marker or mechanism?. Blood 143(13):1206-1207, 2024.
Abstracts
- Jallouk AP, Ge Z, Kaimal V, Furmanak T, Sommer C, Lauron EJ, Sasu BJ, Neelapu SS, Bachireddy P. Cellular mechanisms affecting allogeneic CAR T cell expansion and rejection in large B-cell lymphoma. Blood 142((Supplement 1)):4832, 2023. e-Pub 2023.
- McCurry DM, Ge Z, Lee J, Raparla P, Koehnke T, Pasumarthi R, Leng X, Pasvolsky O, Nguyen V, Maurer K, Li S, Livak K, Azizi E, Soiffer RJ, Shukla S, Majeti R, Ritz J, Wu CJ, Molldrem JJ, Bachireddy P. ASXL1 truncating mutations drives leukemic resistance to T cell attack. Blood 142(Supplement 1):364, 2023. e-Pub 2023.
Patient Reviews
CV information above last modified September 01, 2026